A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens

Journal article

Peer reviewed

Kathleen N. Moore, Bj Rimel, Shefali Agarwal, John Balser, Robert E. Martell and Bradley J. Monk

Journal of clinical oncology, Vol.33(15_suppl), pp.TPS5609-TPS5609

05/20/2015

Abstract

Abstract only

6 Record Views

Title: A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens
Creators: Kathleen N. Moore - University of Oklahoma Health Sciences Center
Bj Rimel - Cedars-Sinai Medical Center
Shefali Agarwal - Tesaro
John Balser - Veristat, Inc., Holliston, MA
Robert E. Martell - Tesaro
Bradley J. Monk - Creighton University
Publication Details: Journal of clinical oncology, Vol.33(15_suppl), pp.TPS5609-TPS5609
Identifiers: 991005969027302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article